Company overview
PGxAI offers AI-driven pharmacogenomics solutions powered by generative AI and real-world evidence for life sciences and pharma. It provides predictive analytics to optimize clinical trial design, identify patient cohorts, and predict drug-gene interactions for CROs and biopharma sponsors. The platform delivers real-time genomic recommendations, automates PGx guideline creation, and personalizes drug treatments like GLP-1 therapies based on genetic profiles.
Pgxai is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include pharmacogenomics ai, generative ai pharma, clinical trial optimization, pgx platform, drug-gene predictions.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://pgx.ai/
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- pharmacogenomics ai, generative ai pharma, clinical trial optimization, pgx platform, drug-gene predictions
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are PGxAI's key capabilities for clinical trials?
- PGxAI leverages machine learning and real-world data to streamline trial design, identify optimal patient cohorts, predict drug-gene interactions, and automate PGx guideline creation for enhanced success and reduced failures.
- What technology powers PGxAI's pharmacogenomics platform?
- The platform uses generative AI models, large language models (LLMs), and retrieval-augmented generation (RAG) integrated with multi-omics data and real-world evidence for precise drug-gene recommendations and sub-second genomic insights.
- Does PGxAI support specific geographies or regulatory standards?
- PGxAI incorporates domain-specific guidelines like CPIC for PGx counseling and operates from Palo Alto, Calif., focusing on U.S.-based precision medicine applications without specified international regulatory details.
Related editorial coverage
- BBSW AI Solution Debuts for Pharma Insights
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
